



PRESS RELEASE

## **New number of shares and votes in Moberg Pharma AB (publ)**

**STOCKHOLM, June 30<sup>th</sup>, 2023, Moberg Pharma AB (publ) announced that the total number of common shares in the company has increased to 10,272,933. The 187,000 newly issued shares are held by the company to secure its commitments under incentive programmes.**

As per June 30<sup>th</sup>, 2023, the total number of shares in Moberg Pharma AB (publ) amounts to 10,272,933. All shares are common shares. The total number of votes are 10,272,933. The increase in the number of shares and votes results from an issue of 187,000 class C shares. The newly issued class C shares have been repurchased and, by virtue of the conversion clause in the articles of association, converted to common shares. As per June 30<sup>th</sup>, 2023, the company holds 445,974 common shares. The shares are intended to ensure fulfilment of commitments under incentive programmes.

### **For additional information, please contact:**

Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: [mark.beveridge@moberpharma.se](mailto:mark.beveridge@moberpharma.se)

### **About this information**

This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8.00 am CEST on June 30<sup>th</sup> 2023 through the contact persons above.

### **About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among others, and the Company's goal is to receive its first market approval and initiate launch preparations of MOB-015 in 2023. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).